Source: International Congress 2014 – Clinical trials in IPF
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
V. Cottin, H. Taniguchi, H. R. Collard, L. Richeldi, S. Stowasser, I. Tschoepe, R. Schlenker-Herceg, G. Raghu (Lyon, Reims, France; Aichi, Japan; San Francisco, Ridgefield, Seattle, United States Of America; Southampton, United Kingdom; Ingelheim am Rhein, Germany). Reduction in disease progression with nintedanib in the INPULSIS™ trials. Eur Respir J 2014; 44: Suppl. 58, 1906

Member's Comments

No comment yet.

Related content which might interest you: Sensitivity analyses from the INPULSIS™ trials of nintedanib Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Acute exacerbation of idiopathic pulmonary fibrosis: Analysis in a post-marketing surveillance of pirfenidone Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Pirfenidone in idiopathic pulmonary fibrosis - description of a German cohort Source: International Congress 2014 – ILDs 4 Year: 2014 Predictors of efficacy of pirfenidone in idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 4 Year: 2014 Safety and efficacy of pirfenidone in severe idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 3 Year: 2014 Intraindividual response to treatment with pirfenidone in two independent European IPF cohorts Source: International Congress 2014 – ILDs 2 Year: 2014 LATE-BREAKING ABSTRACT: Efficacy of Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF): an Italian real life study Source: International Congress 2014 – IPF and surroundings Year: 2014 Morality predictors in acute exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 6 Year: 2014 Pirfenidone and BIBF1120 regulate properties of myofibroblasts Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Pirfenidone therapy for patients with progressive idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 3 Year: 2014 Pregnancy course in patients with interstitial lung diseases Source: International Congress 2014 – ILDs 5 Year: 2014 Platelet activation indices in patients with Idiopathic Pulmonary Fibrosis Source: International Congress 2014 – ILDs 5 Year: 2014 LATE-BREAKING ABSTRACT: Current management of patients with idiopathic pulmonary fibrosis in clinical practice: INSIGHTS-IPF registry Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Evolution of an interstitial lung disease MDT: 5.5 years of data Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Effect of baseline FVC on decline in lung function with nintedanib: Results from the INPULSIS™ trials Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Assessment of telomere length in the combined pulmonary fibrosis and emphysema syndrome Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations Year: 2014 Long term efficacy of pirfenidone therapy in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – ILDs 3 Year: 2014 Effect of design modifications on trial outcomes in idiopathic pulmonary fibrosis (IPF): Analysis of data from ASCEND and CAPACITY (CAP) Source: International Congress 2014 – IPF and surroundings Year: 2014 Prognostic influence of comorbidities in idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – ILDs 2 Year: 2014 Long-term survival analysis: Pirfenidone compared to standard care for the treatment of patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – Clinical trials in IPF Year: 2014